GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Short Percentage of Float

iX Biopharma (SGX:42C) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma Short Percentage of Float Distribution

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Short Percentage of Float falls into.


iX Biopharma (SGX:42C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Short Percentage of Float
Comparable Companies
SGX:BFK ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN SHSE:600196 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
Website
https://www.ixbiopharma.com
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines